Related Experiment Video
Updated: Jul 11, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer]
Henriette Lindberg1, Dorte Lisbet Nielsen, Malgorzata Tuxen
1Herlev Hospital, Onkologisk Afdeling R. lindberg@dadlnet.dk
Abstract:
This review discusses the evidence for endocrine treatment in postmenopausal patients with metastatic breast cancer. First line treatment with non-steroid aromatase inhibitors (AI) yields response rates of 30% and improves progression free survival, but not overall survival, compared to tamoxifen. With second line treatment using steroid AI, estrogen antagonists or selective estrogen receptor modulators prolonged disease stabilisation is achieved in 40% of patients. With third line treatment using steroid AI and estrogen antagonists disease stabilisation is achieved in up to 30% of patients.
Related Concept Videos
Menopause
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists